Actively Recruiting

Phase 1
Age: 18Years - 75Years
All Genders
ID06947304

A Phase 1, Open-Label Study Evaluating the Effect of Miricorilant on Hepatic Lipids in Patients With Presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Led by Corcept Therapeutics · Updated on 2026-02-11

8

Participants Needed

1

Research Sites

N/A

Total Duration

On this page

Sponsors

C

Corcept Therapeutics

Lead Sponsor

U

University of Missouri-Columbia

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effect of Miricorilant on liver fat and metabolism in patients with presumed Metabolic Dysfunction-Associated Steatohepatitis (MASH), a condition related to fatty liver disease. This is a Phase 1, open-label study aiming to understand how Miricorilant influences liver fat production and storage in affected patients. About 8 patients will participate and receive 100 mg of Miricorilant orally once daily for 6 weeks. The total participation lasts up to 16 weeks, including a 6-week screening period before treatment, the 6-week treatment phase, and a 4-week follow-up period. The study does not include a placebo or comparison group. Participants will undergo assessments including MRI scans to measure liver fat content, and tests to evaluate changes in liver fat production before and after treatment. Researchers will monitor safety and treatment effects during and after the study. The primary outcomes focus on changes in hepatic lipogenesis and liver fat measured from baseline to week 6.

CONDITIONS

Brief Title

Evaluation of Miricorilant on Liver Fat in Patients With MASLD

Who Can Participate

Age: 18Years - 75Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Adults aged 18 to 75 years
  • AST > 17 U/L for women and > 20 U/L for men, or eligible liver biopsy within 12 months showing specific NAS and fibrosis scores
  • MRI-PDFF showing ≥ 8% liver steatosis within 4 weeks before baseline
  • Presence of at least one metabolic syndrome characteristic such as type 2 diabetes managed with diet or metformin, or at least three components of metabolic syndrome including elevated blood glucose, hypertension, high triglycerides, low HDL cholesterol, overweight or increased waist circumference
  • Other inclusion criteria may apply
Not Eligible

You will not qualify if you...

  • Participation in another clinical trial for MASH or weight loss within the last 3 months
  • Participation in any other clinical trial within last 3 months or 5 half-lives of treatment
  • Women who are pregnant, planning pregnancy, or lactating
  • BMI less than 18 or greater than 45 kg/m²
  • Significant alcohol consumption exceeding 20 g/day for women or 30 g/day for men within 1 year prior to screening
  • Positive urine drug screen for amphetamines, cocaine, opiates, or cannabinoids
  • Known or suspected cirrhosis or signs of liver decompensation
  • Other chronic liver diseases like hepatitis B or C, autoimmune hepatitis, primary biliary cholangitis, or Wilson's disease
  • History of recent myocardial infarction, unstable angina, or stroke within 3 months
  • Uncontrolled hypertension above specified limits
  • Current use of medications prohibited due to drug interactions with study treatment
  • Contraindications to MRI
  • Other exclusion criteria may apply

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 6 weeks

Participants are screened for eligibility to participate in the trial.

1 screening and enrollment visit

Treatment

Duration - 6 weeks

Participants receive 100 mg of miricorilant orally once daily for 6 weeks.

Weekly visits for up to 6 weeks

Follow-up

Duration - 4 weeks

Participants are monitored for safety and outcomes following treatment completion.

1 follow-up visit

Trial Site Locations

Total: 1 location

1

University of Missouri

Columbia, Missouri, United States, 65211

Actively Recruiting

Loading map...

Research Team

E

Elizabeth Parks, PhD

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Similar Trials

A Phase 1b Study of QX1206 in Type 2 Diabetes Mellitus Patie...

Type 2 Diabetes Mellitus (T2DM)

Actively Recruiting

1 location

A Randomized, Double-Blind, Placebo-Controlled Study of siRN...

Metabolic Dysfunction-Associated SteatoHepatitis (MASH)

Actively Recruiting

71 locations

A Randomized, Double-blind, Placebo-controlled Phase II Stud...

Metabolic Dysfunction-associated Steatohepatitis (MASH)

Actively Recruiting

12 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here